Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

General Information

Progen Pharmaceuticals Limited
PGL
http://www.progen-pharma.com
Biotechnology
11
55

Current Price Data+

Current Price Open High Low Last Close Volume Price Movement
$0.21 $0.19 $0.21 $0.19 $0.21 20300 - ( No change )
  • +Security prices are delayed by least 20 minutes and are indicative only.

Company Overview

Business Description
Progen Pharmaceuticals Limited (PGL) is a biotechnology company focused on the discovery, development and commercialisation of small molecule pharmaceuticals therapeutics for cancer and other serious diseases. PGL develops of the anti-angiogenesis and anti-metastatic oncology products. PGL focuses on two main anti-cancer product developments, which are PG545 and Muparfostat (PI-88). PGL has operations in Australia and USA.
Strategy Analysis
--

Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2014 A -1.8 -3.3 0.0% 0.0 0.0 0.0% 0.0%
2013 A -2.1 -7.5 0.0% 0.0 0.0 0.0% 0.0%
2012 A -3.4 -12.6 0.0% 0.0 0.0 0.0% 0.0%

Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2012 A 2013 F 2014 F 2012 A 2013 F 2014 F 2012 A 2013 F 2014 F
CSL (CSL) $45,939M 0.0899 0.3345 0.0976 34.5959 25.9240 23.6181 1.21% 1.61% 1.98%
Mesoblast (MSB) $1,317M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Monash IVF Group (MVF) $325M 0.0000 1.7120 0.3828 37.5000 13.8277 10.0000 0.00% 4.70% 6.50%
Progen Pharmaceuticals (PGL) $11M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Sirtex Medical (SRX) $1,769M 0.2906 0.6077 0.6087 75.0121 46.6566 29.0021 0.45% 0.63% 1.03%

Financial Summary

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 1.41 0.00
Market 0.96 14.10 1.06 0.48
Sector 0.80 13.20 2.99 0.96

Directors

Name Position Start Date
Mr Indrajit (Jitto) Solomon Arulampalam Executive Chairman 12/07/2013
Dr Christopher Harvey Non-Executive Director 16/03/2015
Dr Hongjen Chang Non-Executive Director 29/11/2013

Management

Name Position
B.Tillack Chief Executive Officer - Pharmasynth
Blair Lucas Company Secretary
F. Lankesheer Director - Business Development and Legal
K. Dredge Director - Drug Development
L. Horobin General Manager- Finance

Substantial Shareholders

Holding Name
7,922,742 (14.33%) JP Morgan Nominees Australia Limited
6,700,000 (12.12%) TBG Inc
5,312,116 (9.61%) HSBC Custody Nominees (Australia) Limited

Calendar of Events

Date Event
26 February 2016 Report (Interim)
12 November 2015 Report (Annual)
28 September 2015 Report (Annual)
25 August 2015 Report (Prelim)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at www.morningstar.com.au/fsg.asp.